Viking Therapeutics, Inc. $VKTX Position Reduced by Voya Investment Management LLC

Voya Investment Management LLC lessened its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 6.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 366,379 shares of the biotechnology company’s stock after selling 23,761 shares during the quarter. Voya Investment Management LLC owned approximately 0.33% of Viking Therapeutics worth $8,848,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Quarry LP lifted its holdings in shares of Viking Therapeutics by 1,621.4% during the 1st quarter. Quarry LP now owns 1,205 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,135 shares during the last quarter. Parallel Advisors LLC lifted its holdings in Viking Therapeutics by 64.8% in the 1st quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 536 shares during the last quarter. NBC Securities Inc. lifted its holdings in Viking Therapeutics by 222,100.0% in the 1st quarter. NBC Securities Inc. now owns 2,222 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 2,221 shares during the last quarter. Flaharty Asset Management LLC acquired a new stake in Viking Therapeutics in the 1st quarter worth approximately $56,000. Finally, JNBA Financial Advisors acquired a new stake in Viking Therapeutics in the 1st quarter worth approximately $56,000. Hedge funds and other institutional investors own 76.03% of the company’s stock.

Insider Buying and Selling at Viking Therapeutics

In related news, CFO Greg Zante sold 4,266 shares of Viking Therapeutics stock in a transaction that occurred on Thursday, July 3rd. The stock was sold at an average price of $27.76, for a total transaction of $118,424.16. Following the completion of the sale, the chief financial officer directly owned 168,660 shares of the company’s stock, valued at approximately $4,682,001.60. This trade represents a 2.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Marianna Mancini sold 4,266 shares of Viking Therapeutics stock in a transaction that occurred on Thursday, July 3rd. The stock was sold at an average price of $27.77, for a total value of $118,466.82. Following the sale, the chief operating officer directly owned 377,535 shares of the company’s stock, valued at approximately $10,484,146.95. The trade was a 1.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 35,421 shares of company stock worth $984,405 over the last ninety days. 4.10% of the stock is currently owned by corporate insiders.

Viking Therapeutics Stock Down 1.6%

Viking Therapeutics stock opened at $23.69 on Wednesday. Viking Therapeutics, Inc. has a 12-month low of $18.92 and a 12-month high of $81.73. The business’s 50-day simple moving average is $30.82 and its 200 day simple moving average is $28.14. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of -15.48 and a beta of 0.73.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, July 23rd. The biotechnology company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.14). The business’s quarterly revenue was up NaN% on a year-over-year basis. During the same period in the prior year, the business earned ($0.20) earnings per share. As a group, sell-side analysts expect that Viking Therapeutics, Inc. will post -1.56 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $102.00 target price on shares of Viking Therapeutics in a report on Tuesday, August 19th. Citigroup boosted their target price on Viking Therapeutics from $31.00 to $38.00 and gave the stock a “neutral” rating in a report on Thursday, July 24th. Finally, Raymond James Financial cut their price target on Viking Therapeutics from $125.00 to $122.00 and set a “strong-buy” rating for the company in a report on Thursday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Viking Therapeutics has an average rating of “Buy” and an average target price of $87.50.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.